Merck & Co. (MRK) posted $63.62 billion in revenue with a 23.1% free cash flow margin, reflecting robust financial health and enhanced negotiating power in the pharmaceutical market. These results underscore Merck’s ability to balance growth, profitability, and strategic investments across its portfolio.

On the clinical front, Bicara Therapeutics received FDA breakthrough designation for ficerafusp alfa in combination with Merck’s Keytruda, targeting HPV-negative metastatic head and neck squamous cell carcinoma. This milestone highlights ongoing innovations in Merck’s oncology pipeline and potential new treatment options for challenging cancers.

The combination of solid financial performance and advanced pipeline developments positions Merck for continued growth and influence in both commercial and clinical arenas.